Behavioral Health Intelligence Dashboard
Regulation, markets, pipeline status, and news signals across pharma, psychedelics, cannabis, and digital health — monitored from public sources and reviewed with editorial judgment.
How this is built →Regulatory Tracker
Recent public filings and regulatory signals from monitored government sources.
Market Movers
Tracked equities connected to behavioral health: pharma psychiatry, psychedelics, cannabis, and digital health.
Movers
| Ticker | Last | % |
|---|---|---|
| TCNNF | 9.67 | +14.62% |
| CURLF | 3.56 | +12.66% |
| CMPS | 13.00 | +9.06% |
| GHRS | 23.78 | +6.26% |
| Ticker | Last | % |
|---|---|---|
| LFMD | 4.37 | -4.79% |
| LLY | 1095.92 | -2.74% |
| ACHC | 23.26 | -2.10% |
| JNJ | 226.73 | -1.76% |
News Wire
Short signals from Behavioral Wire's coverage and monitored public sources.
News wire
Pipeline · Watchlist
Key programs currently tracked in Behavioral Wire's public pipeline dataset.
Pipeline
Key programs in development · scroll →Zuranolone (Zurzuvae)
Postpartum depression
AXS-05 (Auvelity)
Major depressive disorder
Esketamine (Spravato)
Treatment-resistant depression
Cobenfy (xanomeline-trospium)
Schizophrenia
Navacaprant (NMRA-140)
Major depressive disorder
Emraclidine
Schizophrenia
COMP360 psilocybin
Treatment-resistant depression
MM120 (LSD D-tartrate)
Generalized anxiety disorder
MDMA-assisted therapy
PTSD
CYB003 (deuterated psilocin)
Major depressive disorder
GH001 (inhaled mebufotenin)
Treatment-resistant depression
BPL-003 (intranasal mebufotenin)
Treatment-resistant depression
Epidiolex (cannabidiol)
Epilepsy; behavioral indications explored
Nabiximols (Sativex)
Multiple sclerosis spasticity
Zygel (CBD transdermal gel)
Fragile X syndrome
Rejoyn
Major depressive disorder (adjunct)
CT-155
Schizophrenia (negative symptoms)
Sleepio / Daylight
Insomnia and anxiety